A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a down syndrome screening program

No Thumbnail Available
File version
Author(s)
Ayres, AC
Whitty, JA
Ellwood, DA
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2015
Size
File type(s)
Location
License
Abstract

Noninvasive prenatal testing (NIPT) can analyze cell-free DNA of placental origin in maternal serum for trisomy 21. The detection rate is 99.5%, and the false-positive rate (FPR) is 0.2%. Noninvasive prenatal testing is recommended only for high-risk women after conventional screening. Noninvasive prenatal testing is deemed a screening modality, and invasive diagnostic testing is required for confirmation following a “positive” result. The present study was performed to evaluate NIPT by comparing 4 strategies examining cost-effectiveness and budget impacts for health care systems and parturients.

Journal Title

Obstetrical and Gynecological Survey

Conference Title
Book Title
Edition
Volume

70

Issue

2

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Paediatrics and Reproductive Medicine

Persistent link to this record
Citation

Ayres, AC; Whitty, JA; Ellwood, DA, A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a down syndrome screening program, Obstetrical and Gynecological Survey, 2015, 70 (2), pp. 63-65

Collections